Background/Objectives: Thrombocytopenia (TP) is common in critically ill patients, but the significance of its severity, timing, persistence, and admission subthreshold platelet count (PC) remains uncertain. We evaluated these associations with mortality in a medical ICU. Methods: In this prospective cohort study, 280 adults admitted to a tertiary medical ICU (September 2023–August 2024) were followed until ICU discharge or death. TP was defined as a PC < 150 × 109/L, and admission STP as a first ICU PC of 150–199 × 109/L, irrespective of later platelet course. Outcomes included mortality (ICU, hospital, 28-day, 90-day), organ support, and major complications. Results: TP occurred in 118 patients (42.1%), with higher crude mortality at all time points (all p < 0.001). In the lagged time-dependent Cox analysis, ICU-acquired TP was associated with ICU mortality in the minimally adjusted model (HR 1.93, CI 1.12–3.35; p = 0.018) but not after adjustment for invasive MV (aHR 1.31, CI 0.72–2.40; p = 0.372). Admission TP was not significantly associated with ICU mortality in the adjusted model (aHR 1.22, CI 0.74–2.00; p = 0.436). Admission PC showed limited discrimination (AUC 0.583, CI 0.508–0.657). No statistically significant difference was found between admission STP and PC ≥ 200 × 109/L (exploratory comparison, wide CIs). Conclusions: TP was associated with disease severity and worse crude outcomes, but adjusted longitudinal analyses did not establish an independent association with ICU mortality. No statistically significant difference was found for admission STP versus PC ≥ 200 × 109/L in this exploratory comparison; this should not be interpreted as clinical equivalence or as indicating no prognostic value.
1 January 2026 in Journal of Clinical Practice and Research
Objective: Myeloid-derived suppressor cells (MDSCs) are immature myeloid progenitors, including monocytic and granulocytic subgroups (M-MDSCs and PMN-MDSCs). They exhibit immunoregulatory and immunosuppressive properties by limiting immune-mediated pathology and protecting the host from destructive inflammatory damage. Graft-versus-host disease (GVHD) comprises a series of immune-mediated inflammatory events in which donor-derived T cells target the tissues and organs of the transplant recipient. This study aims to evaluate the behavior of MDSCs during GVHD in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). Materials and Methods: Fifteen patients who underwent allogeneic HSCT were included in the study. MDSCs and their subsets were identified and characterized by flow cytometry on days 0, 30, 60, and 90 post-engraftment. Results: The median frequency of monocytic MDSCs (M-MDSCs) on the first day of engraftment was significantly higher in patients without GVHD than in those who developed GVHD. Furthermore, the expansion of M-MDSCs occurred significantly earlier than that of the other MDSC subset. Conclusion: Monocytic MDSCs play a key regulatory role in limiting GVHD and may serve as potential therapeutic targets for GVHD prevention or treatment.
Background: Treatment strategies for myelodysplastic syndromes (MDS) range from supportive care to disease-modifying therapies, depending on risk stratification and patient characteristics. Hypomethylating agents (HMAs) remain the standard treatment for higher-risk disease, whereas allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only potentially curative option. This study evaluated real-world survival outcomes and prognostic factors in patients with MDS treated with HMAs or allo-HSCT. Methods: A total of 79 patients with MDS who received azacitidine, decitabine, or allo-HSCT were retrospectively analyzed. Overall survival (OS) was evaluated using Kaplan–Meier and Cox proportional hazards analyses. To address potential immortal time bias, a prespecified 6-month landmark analysis was additionally performed. Results: Median OS was 14.9 months (95% CI, 9.9–20.0) with azacitidine, 10.0 months (95% CI, 6.8–13.2) with decitabine, and 48.0 months (95% CI, 19.9–76.1) after allo-HSCT. Patients undergoing allo-HSCT were significantly younger and had better ECOG performance status than those receiving HMAs. After adjustment for age, ECOG performance status, and IPSS-R risk category, treatment modality remained significantly associated with OS in the multivariable Cox regression model. In the prespecified 6-month landmark analysis, the survival advantage associated with allo-HSCT remained significant, although the adjusted association was attenuated. Conclusions: In this real-world cohort of actively treated patients with MDS, allo-HSCT was associated with longer overall survival than HMAs. Although this association persisted after adjustment for major clinical confounders and in a landmark analysis addressing immortal time bias, residual confounding related to treatment selection cannot be excluded. These findings should therefore be interpreted as an association rather than evidence of a causal treatment effect.